About - MTEM :

Molecular Templates, Inc., a clinical stage biopharmaceutical company, focuses on the discovery and development of biologic therapeutics for the treatment of cancer and other serious diseases. The company primarily develops a pipeline of therapies through its proprietary biologic engineered toxin body (ETB) drug platform. The company is developing MT-5111, an ETB candidate that is in Phase I clinical trial for the treatment of HER2-positive cancers; MT-0169, which is in Phase I clinical trial to treat relapsed/refractory myeloma patients; and MT-6402 in that is in Phase I clinical trial for PD-1/PD-L1 antibody relapsed/refractory patients. Its pipeline of ETBs in development for other targets, including CTLA-4, TIGIT, TROP2, BCMA, SLAMF-7, and CD45. The company has a collaboration agreement with Bristol Myers Squibb to discover and develop novel products containing ETBs directed to multiple targets. Molecular Templates, Inc. was founded in 2001 and is headquartered in Austin, Texas.

Employees - 62, CEO - Dr. Eric E. Poma Ph.D., Sector - Healthcare, Country - US, Market Cap - 0.48M

Altman ZScore(max is 10): -24.97, Piotroski Score(max is 10): 2, Working Capital: $4336000, Total Assets: $26697000, Retained Earnings: $-460417000, EBIT: -16174000, Total Liabilities: $19586000, Revenue: $25470000

- Current Price $0.16 - Analyst Target Price $18.00

Stats & Key Metrics
TickerMTEM
Index-
Curent Price 0.16
Change-54.29%
Market Cap0.48M
Average Volume14.70M
Income-15.63M
Sales25.47M
Book Value/Share1.08
Cash/Share3.22
Dividend Est-
Dividend TTM-
Dividend Ex-Date-
Employees62
Moving Avg 20days-57.85%
Moving Avg 50days-65.52%
Moving Avg 200days-87.35%
Shares Outstanding6.58M
Earnings DateAug 14 AMC
Inst. Ownership41.02%
Key Ratios & Margins
Price/Earnings-
Forwad P/E-
PE Growth-
Price/Sales0.02
Price/Book0.15
Price/Cash0.05
Price/FCF-
Quick Ratio1.56
Current Ratio1.56
Debt/Equity1.55
Return on Assets-50.24%
Return on Equity-929.14%
Return on Investment-100.81%
Gross Margin80.33%
Ops Margin-74.02%
Profit Margin-61.35%
RSI30.15
BETA(β)1.16
From 52week Low-45.76%
From 52week High-96.12%
Earnings & Valuation
EPS-2.70
EPS next Year-
EPS next Qtr-
EPS this Year-
EPS next 5 Year-
EPS past 5 Year34.83%
Sales past 5 Year59.75%
EPS Y/Y78.46%
Sales Y/Y-49.41%
EPS Q/Q57.32%
Sales Q/Q-91.67%
Sales Surprise33.02%
EPS Surprise14.58%
ATR(14)0.09
Perf Week-60.00%
Perf Month-58.76%
Perf Quarter-87.50%
Perf Year-95.65%
Perf YTD-95.71%
Target Price18.00

AryaFin Engine© - An AI FinTech Venture - 2024 Disclaimer